Related references
Note: Only part of the references are listed.An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes
Taryn L. Reddy et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients
Hideki Kusagaya et al.
BMC PULMONARY MEDICINE (2012)
Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis
Kentaro Watanabe et al.
RESPIRATORY INVESTIGATION (2012)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias
Yuji Ohtsuki et al.
MEDICAL MOLECULAR MORPHOLOGY (2007)
Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients
A Dosanjh
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Idiopathic pleuroparenchymal fibroelastosis - Description of a novel clinicopathologic entity
SK Frankel et al.
CHEST (2004)
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases
H Ohnishi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis
KE Greene et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis
H Takahashi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
